Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Down 18.6% in January

Aspira Women’s Health Inc. (NASDAQ:AWH) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totalling 356,900 shares, a decline of 18.6% from the December 31st total of 438,500 shares. Based on an average daily volume of 100,900 shares, the days-to-cover ratio is currently 3.5 days. Approximately 2.9% of the shares of the stock are sold short.

Aspira Women’s Health Price Performance

Shares of AWH stock traded down $0.01 during mid-day trading on Thursday, hitting $0.40. 24,014 shares of the stock traded hands, compared to its average volume of 74,911. Aspira Women’s Health has a 52-week low of $0.36 and a 52-week high of $5.62. The stock has a market cap of $6.70 million, a P/E ratio of -0.33 and a beta of 1.42. The stock’s fifty day moving average is $0.68 and its two-hundred day moving average is $0.89.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Aspira Women’s Health in a research report on Sunday, January 12th. They issued a “hold” rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 33.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 316,294 shares of the company’s stock after purchasing an additional 79,898 shares during the quarter. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $256,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.